Medtronic Focuses on a Preventable Patient Safety Issue
SAN DIEGO – October 28, 2015 – Medtronic plc (NYSE: MDT) today announced findings from two clinical studies, the first validating the clinical utility of the Integrated Pulmonary Index™ (IPI) in the post anesthesia care unit (PACU) to identify respiratory adverse events (RAE) and the second, a study on the cost-effectiveness of capnography in gastrointestinal (GI) sedation. The study results highlight the need for clinicians to actively monitor for respiratory compromise following general anesthesia and procedural sedation with both pulse oximetry and capnography. These data were presented at the ANESTHESIOLOGY® 2015 annual meeting in San Diego.
Respiratory failure is the second-most frequently occurring preventable safety adverse event¹ causing higher mortality rates, longer hospital and intensive care unit stays, and billions of additional healthcare dollars spent each year.² , ³It is rapidly becoming the third most costly hospital inpatient expense in the U.S.² Respiratory Compromise, which consists of respiratory insufficiency, failure and arrest, dramatically increases the likelihood of adverse outcomes and cost of patient care. Currently, 13 million patients use patient-controlled analgesia each year and up to 678,000 of these patients experience life-threatening, opioid-induced respiratory depression.
Para acceder al sitio, haga Clic Aquí